Rifampin, Rifapentine, and Rifabutin Are Active Against Intracellular Periprosthetic Joint Infection-Associated Staphylococcus Epidermidis

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2020 Nov 17

PMID 33199387

Citations 3

Authors

Cody Fisher

Robin Patel

Affiliations

Soon will be listed here.

Abstract

is a major cause of periprosthetic joint infection (PJI); its intracellular persistence within osteoblasts may compromise therapy if that therapy is not intracellularly active. The intracellular activity of rifampin, rifapentine, and rifabutin was assessed against five rifampin-susceptible and two rifampin-resistant isolates. Compared to no treatment, treatment resulted in a ≥2-fold log reduction of intracellular rifampin-susceptible, but not rifampin-resistant, These findings show activity of rifampin, rifapentine, and rifabutin against intraosteoblast PJI-associated .

Citing Articles

Should We Use Rifampicin in Periprosthetic Joint Infections Caused by Staphylococci When the Implant Has Been Exchanged? A Multicenter Observational Cohort Study.

Kramer T, Soriano A, Tedeschi S, Chen A, Tattevin P, Senneville E Open Forum Infect Dis. 2023; 10(10):ofad491.

PMID: 37901121 PMC: 10604993. DOI: 10.1093/ofid/ofad491.

Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis.

Karau M, Schmidt-Malan S, Cunningham S, Mandrekar J, Pritt B, Keepers T Antimicrob Agents Chemother. 2021; 66(1):e0170321.

PMID: 34723626 PMC: 8765317. DOI: 10.1128/AAC.01703-21.

Staphylococcal trafficking and infection-from 'nose to gut' and back.

Raineri E, Altulea D, van Dijl J FEMS Microbiol Rev. 2021; 46(1).

PMID: 34259843 PMC: 8767451. DOI: 10.1093/femsre/fuab041.

References

Wi Y, Greenwood-Quaintance K, Brinkman C, Lee J, Howden B, Patel R . Rifampicin resistance in Staphylococcus epidermidis: molecular characterisation and fitness cost of rpoB mutations. Int J Antimicrob Agents. 2017; 51(5):670-677. DOI: 10.1016/j.ijantimicag.2017.12.019. View

Becker A, Kreitmann L, Triffaut-Fillit C, Valour F, Mabrut E, Forestier E . Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to treated with a debridement, antibiotics and implant retention (DAIR): a retrospective multicenter study in France. J Bone Jt Infect. 2020; 5(1):28-34. PMC: 7045531. DOI: 10.7150/jbji.40333. View

Mohamed W, Sommer U, Sethi S, Domann E, Thormann U, Schutz I . Intracellular proliferation of S. aureus in osteoblasts and effects of rifampicin and gentamicin on S. aureus intracellular proliferation and survival. Eur Cell Mater. 2014; 28:258-68. DOI: 10.22203/ecm.v028a18. View

Zimmerli W . Infection and musculoskeletal conditions: Prosthetic-joint-associated infections. Best Pract Res Clin Rheumatol. 2006; 20(6):1045-63. DOI: 10.1016/j.berh.2006.08.003. View

Aristoff P, Garcia G, Kirchhoff P, Showalter H . Rifamycins--obstacles and opportunities. Tuberculosis (Edinb). 2010; 90(2):94-118. DOI: 10.1016/j.tube.2010.02.001. View

Tande A, Patel R . Prosthetic joint infection. Clin Microbiol Rev. 2014; 27(2):302-45. PMC: 3993098. DOI: 10.1128/CMR.00111-13. View

Osmon D, Berbari E, Berendt A, Lew D, Zimmerli W, Steckelberg J . Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2012; 56(1):e1-e25. DOI: 10.1093/cid/cis803. View

Mack D, Siemssen N, Laufs R . Parallel induction by glucose of adherence and a polysaccharide antigen specific for plastic-adherent Staphylococcus epidermidis: evidence for functional relation to intercellular adhesion. Infect Immun. 1992; 60(5):2048-57. PMC: 257114. DOI: 10.1128/iai.60.5.2048-2057.1992. View

Karau M, Schmidt-Malan S, Albano M, Mandrekar J, Rivera C, Osmon D . Novel Use of Rifabutin and Rifapentine to Treat Methicillin-Resistant Staphylococcus aureus in a Rat Model of Foreign Body Osteomyelitis. J Infect Dis. 2020; 222(9):1498-1504. DOI: 10.1093/infdis/jiaa401. View

10.

Perez K, Patel R . Survival of Staphylococcus epidermidis in Fibroblasts and Osteoblasts. Infect Immun. 2018; 86(10). PMC: 6204734. DOI: 10.1128/IAI.00237-18. View

11.

Sanchez Jr C, Shiels S, Tennent D, Hardy S, Murray C, Wenke J . Rifamycin Derivatives Are Effective Against Staphylococcal Biofilms In Vitro and Elutable From PMMA. Clin Orthop Relat Res. 2015; 473(9):2874-84. PMC: 4523531. DOI: 10.1007/s11999-015-4300-3. View

12.

Abad L, Josse J, Tasse J, Lustig S, Ferry T, Diot A . Antibiofilm and intraosteoblastic activities of rifamycins against Staphylococcus aureus: promising in vitro profile of rifabutin. J Antimicrob Chemother. 2020; 75(6):1466-1473. DOI: 10.1093/jac/dkaa061. View

13.

Albano M, Karau M, Greenwood-Quaintance K, Osmon D, Oravec C, Berry D . Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection. Antimicrob Agents Chemother. 2019; 63(11). PMC: 6811393. DOI: 10.1128/AAC.00959-19. View

14.

Valour F, Trouillet-Assant S, Rasigade J, Lustig S, Chanard E, Meugnier H . Staphylococcus epidermidis in orthopedic device infections: the role of bacterial internalization in human osteoblasts and biofilm formation. PLoS One. 2013; 8(6):e67240. PMC: 3696042. DOI: 10.1371/journal.pone.0067240. View